Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 106 participants.
Also called NCT06668389
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 106 participants
- Sponsor
- Registry
-
NCT06668389
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Hong Kong SAR China
- Registry status
- Recruiting
Technical summary
Registry record NCT06668389. Randomized; no masking; primary purpose treatment. Start 2025-05-12 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
- Acronym
- STEPS
- Condition
- Congenital Heart Disease
- Condition
- Repaired Tetralogy of Fallot (rTOF)
- Condition
- Pulmonary Regurgitation
- Condition
- Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor
- Condition
- Dapagliflozin (Forxiga)
- Intervention (Drug)
- SGLT2 inhibitor (Dapagliflozin 10mg)
- Lead sponsor
- The University of Hong Kong
Record details
- Record id
cardio:ct-nct06668389- Content hash
2d0e2f3c6d9ae59b1e4cb28bdf64e14bd221edfc8893c099bbe649d5cce22ee6